Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial.
- DOI
- 10.1016/j.jtho.2025.07.117
- Published
- 2025 Oct
- Container
- Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jtho.2025.07.117,
title = {Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial.},
author = {Cho BC and Li W and Spira AI and Sauder M and Feldman J and Bozorgmehr F and Mak M and Smith J and Voon PJ and Liu B and Tian P and Tan JL and Yang CT and Shih JY and Karadurmus N and Cundom JE and Bertollo G and Cicin I and Nieva J and Ortega-Granados AL and Tomasini P and Nguyen D and Felip E and Schuchard J and Murphy SP and Anderson BG and Romero T and Xia Y and Sheng S and Bauml JM and Mahadevia PJ and Kam J and Nematian-Samani M and Simoes J and Wildgust M and Girard N},
year = {2025},
journal = {Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
doi = {10.1016/j.jtho.2025.07.117},
url = {https://doi.org/10.1016/j.jtho.2025.07.117}
}RIS
TY - JOUR TI - Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial. AU - Cho BC AU - Li W AU - Spira AI AU - Sauder M AU - Feldman J AU - Bozorgmehr F AU - Mak M AU - Smith J AU - Voon PJ AU - Liu B AU - Tian P AU - Tan JL AU - Yang CT AU - Shih JY AU - Karadurmus N AU - Cundom JE AU - Bertollo G AU - Cicin I AU - Nieva J AU - Ortega-Granados AL AU - Tomasini P AU - Nguyen D AU - Felip E AU - Schuchard J AU - Murphy SP AU - Anderson BG AU - Romero T AU - Xia Y AU - Sheng S AU - Bauml JM AU - Mahadevia PJ AU - Kam J AU - Nematian-Samani M AU - Simoes J AU - Wildgust M AU - Girard N PY - 2025 JO - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer DO - 10.1016/j.jtho.2025.07.117 UR - https://doi.org/10.1016/j.jtho.2025.07.117 ER -
APA
BC, C., W, L., AI, S., M, S., J, F., F, B., M, M., J, S., PJ, V., B, L., P, T., JL, T., CT, Y., JY, S., N, K., JE, C., G, B., I, C., J, N., AL, O., P, T., D, N., E, F., J, S., SP, M., BG, A., T, R., Y, X., S, S., JM, B., PJ, M., J, K., M, N., J, S., M, W., & N, G. (2025). Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. https://doi.org/10.1016/j.jtho.2025.07.117
Source records
- pubmed · retrieved 2026-09-26T04:17:48.045Z
- europe-pmc · retrieved 2026-09-26T04:17:48.057Z